Effect of cholinergic drugs on acute and chronic morphine dependence. 1982

N Padmanabha Pillai, and S Ramaswamy, and V Gopalakrishnan, and M N Ghosh

The effect of both centrally and peripherally acting cholinergic drugs on acute and chronic morphine dependence was investigated. The quaternary ammonium drugs, neostigmine and atropine methyl bromide which cross the blood-brain barrier with difficulty, significantly altered the withdrawal jumping and wet shakes in a similar manner to that exhibited by centrally acting tertiary drugs viz. physostigmine and atropine sulphate. The cholinergic agonists inhibited the withdrawal signs while the antagonists enhanced the same. This suggests that the peripheral cholinergic mechanisms are also involved apart from the central mechanisms in the phenomena of acute and chronic morphine dependence.

UI MeSH Term Description Entries
D008297 Male Males
D009021 Morphine Dependence Strong dependence, both physiological and emotional, upon morphine. Morphine Abuse,Morphine Addiction,Abuse, Morphine,Addiction, Morphine,Dependence, Morphine
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D009388 Neostigmine A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier. Synstigmin,Neostigmine Bromide,Neostigmine Methylsulfate,Polstigmine,Proserine,Prostigmin,Prostigmine,Prozerin,Syntostigmine,Bromide, Neostigmine,Methylsulfate, Neostigmine
D010277 Parasympathomimetics Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. Parasympathomimetic Agents,Parasympathomimetic Drugs,Parasympathomimetic Effect,Parasympathomimetic Effects,Agents, Parasympathomimetic,Drugs, Parasympathomimetic,Effect, Parasympathomimetic,Effects, Parasympathomimetic
D010830 Physostigmine A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. Eserine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001285 Atropine An alkaloid, originally from Atropa belladonna, but found in other plants, mainly SOLANACEAE. Hyoscyamine is the 3(S)-endo isomer of atropine. AtroPen,Atropin Augenöl,Atropine Sulfate,Atropine Sulfate Anhydrous,Atropinol,Anhydrous, Atropine Sulfate,Augenöl, Atropin,Sulfate Anhydrous, Atropine,Sulfate, Atropine
D013375 Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug. Drug Withdrawal Symptoms,Withdrawal Symptoms,Drug Withdrawal Symptom,Substance Withdrawal Syndromes,Symptom, Drug Withdrawal,Symptom, Withdrawal,Symptoms, Drug Withdrawal,Symptoms, Withdrawal,Syndrome, Substance Withdrawal,Syndromes, Substance Withdrawal,Withdrawal Symptom,Withdrawal Symptom, Drug,Withdrawal Symptoms, Drug,Withdrawal Syndrome, Substance,Withdrawal Syndromes, Substance

Related Publications

N Padmanabha Pillai, and S Ramaswamy, and V Gopalakrishnan, and M N Ghosh
January 1986, General pharmacology,
N Padmanabha Pillai, and S Ramaswamy, and V Gopalakrishnan, and M N Ghosh
June 1959, Bollettino della Societa italiana di biologia sperimentale,
N Padmanabha Pillai, and S Ramaswamy, and V Gopalakrishnan, and M N Ghosh
April 1975, The Journal of pharmacology and experimental therapeutics,
N Padmanabha Pillai, and S Ramaswamy, and V Gopalakrishnan, and M N Ghosh
January 1980, Stroke,
N Padmanabha Pillai, and S Ramaswamy, and V Gopalakrishnan, and M N Ghosh
January 1969, Indian journal of physiology and pharmacology,
N Padmanabha Pillai, and S Ramaswamy, and V Gopalakrishnan, and M N Ghosh
January 1975, Advances in biochemical psychopharmacology,
N Padmanabha Pillai, and S Ramaswamy, and V Gopalakrishnan, and M N Ghosh
February 2017, Physiology & behavior,
N Padmanabha Pillai, and S Ramaswamy, and V Gopalakrishnan, and M N Ghosh
January 1987, Neuropharmacology,
N Padmanabha Pillai, and S Ramaswamy, and V Gopalakrishnan, and M N Ghosh
August 2013, Pharmacology, biochemistry, and behavior,
N Padmanabha Pillai, and S Ramaswamy, and V Gopalakrishnan, and M N Ghosh
March 1977, Psychopharmacology,
Copied contents to your clipboard!